Advertisement
Screener

GSK plc (GSK) Form 6-K: Report of foreign private issuer, 2026, Page 2

2.5 / 5 stars · 20/40 Roast Me

Add as a preferred source on Google

GSK plc Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2026-04-10: Form 6-K; Period of report 2026-04-10; Description TRANSACTION IN OWN SHARES; Document a8989z.htm.
  • 2026-04-09: Form 6-K; Period of report 2026-04-09; Description DIRECTOR/PDMR SHAREHOLDING; Document a8641z.htm.
  • 2026-04-09: Form 6-K; Period of report 2026-04-09; Description TRANSACTION IN OWN SHARES; Document a7076z.htm.
  • 2026-04-08: Form 6-K; Period of report 2026-04-08; Description EXDENSUR APPROVED FOR CRSWNP IN CHINA; Document a5397z.htm.
FiledFormPeriod of reportDescriptionDocument
2026-04-106-K2026-04-10TRANSACTION IN OWN SHARESa8989z.htm
2026-04-096-K2026-04-09DIRECTOR/PDMR SHAREHOLDINGa8641z.htm
2026-04-096-K2026-04-09TRANSACTION IN OWN SHARESa7076z.htm
2026-04-086-K2026-04-08EXDENSUR APPROVED FOR CRSWNP IN CHINAa5397z.htm
2026-04-086-K2026-04-08TRANSACTION IN OWN SHARESa5293z.htm
2026-04-076-K2026-04-07TRANSACTION IN OWN SHARESa3393z.htm
2026-04-026-K2026-04-02TRANSACTION IN OWN SHARESa1422z.htm
2026-04-016-K2026-04-01DIRECTOR/PDMR SHAREHOLDINGa0866z.htm
2026-04-016-K2026-04-01TOTAL VOTING RIGHTSa1147z.htm
2026-04-016-K2026-04-01TRANSACTION IN OWN SHARESa9378y.htm
2026-04-016-K2026-04-01VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDINGa8796y.htm
2026-03-316-K2026-03-31TRANSACTION IN OWN SHARESa6988y.htm
2026-03-306-K2026-03-30BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINAa5265y.htm
2026-03-306-K2026-03-30EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINAa5391y.htm
2026-03-306-K2026-03-30TRANSACTION IN OWN SHARESa5267y.htm
2026-03-276-K2026-03-27TRANSACTION IN OWN SHARESa3462y.htm
2026-03-276-K2026-03-27BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMAa2767y.htm
2026-03-266-K2026-03-26TRANSACTION IN OWN SHARESa1561y.htm
2026-03-256-K2026-03-25DIRECTOR/PDMR SHAREHOLDINGa1265y.htm
2026-03-256-K2026-03-25NOTICE OF AGMa0911y.htm
2026-03-256-K2026-03-25TRANSACTION IN OWN SHARESa9710x.htm
2026-03-246-K2026-03-24TRANSACTION IN OWN SHARESa7704x.htm
2026-03-236-K2026-03-23DIRECTOR/PDMR SHAREHOLDINGa7048x.htm
2026-03-236-K2026-03-23ADMISSION TO TRADINGa7370x.htm
2026-03-236-K2026-03-23GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUSa5841x.htm
2026-03-236-K2026-03-23TRANSACTION IN OWN SHARESa5614x.htm
2026-03-206-K2026-03-20TRANSACTION IN OWN SHARESa3920x.htm
2026-03-196-K2026-03-19LYNAVOY (LINERIXIBAT) APPROVED BY US FDAa3294x.htm
2026-03-196-K2026-03-19TRANSACTION IN OWN SHARESa2223x.htm
2026-03-186-K2026-03-18DIRECTOR/PDMR SHAREHOLDINGa1911x.htm
2026-03-186-K2026-03-18TRANSACTION IN OWN SHARESa0360x.htm
2026-03-176-K2026-03-17DIRECTOR/PDMR SHAREHOLDINGa0155x.htm
2026-03-176-K2026-03-17TRANSACTION IN OWN SHARESa8482w.htm
2026-03-166-K2026-03-16TRANSACTION IN OWN SHARESa6694w.htm
2026-03-136-K2026-03-13US FDA APPROVES AREXVY FOR ADULTS 18-49 AIRa6063w.htm
2026-03-136-K2026-03-13TRANSACTION IN OWN SHARESa4805w.htm
2026-03-126-K2026-03-12DIRECTOR/PDMR SHAREHOLDINGa4233w.htm
2026-03-126-K2026-03-12TRANSACTION IN OWN SHARESa3035w.htm
2026-03-116-K2026-03-11TRANSACTION IN OWN SHARESa1171w.htm
2026-03-106-K2026-03-10TRANSACTION IN OWN SHARESa9431v.htm
2026-03-096-K2026-03-09BOARD COMMITTEE CHANGEa8724v.htm
2026-03-096-K2026-03-09GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTSa8361v.htm
2026-03-096-K2026-03-09TRANSACTION IN OWN SHARESa7559v.htm
2026-03-066-K2026-03-06FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-Fa7307v.htm
2026-03-066-K2026-03-06TRANSACTION IN OWN SHARESa5719v.htm
2026-03-056-K2026-03-05GSK PUBLISHES ANNUAL REPORT 2025a4935v.htm
2026-03-056-K2026-03-05TRANSACTION IN OWN SHARESa3887v.htm
2026-03-046-K2026-03-04DIRECTOR/PDMR SHAREHOLDINGa3565v.htm
2026-03-046-K2026-03-04TRANSACTION IN OWN SHARESa2048v.htm
2026-03-036-K2026-03-03GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICSa1763v.htm
2026-03-036-K2026-03-03TRANSACTION IN OWN SHARESa0154v.htm
2026-03-026-K2026-03-02TRANSACTION IN OWN SHARESa8013u.htm
2026-03-026-K2026-03-02TOTAL VOTING RIGHTSa9800u.htm
2026-02-276-K2026-02-27DIRECTOR/PDMR SHAREHOLDINGa7607u.htm
2026-02-276-K2026-02-27TRANSACTION IN OWN SHARESa6052u.htm
2026-02-266-K2026-02-26LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINAa4535u.htm
2026-02-266-K2026-02-26BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEWa4533u.htm
2026-02-266-K2026-02-26TRANSACTION IN OWN SHARESa4329u.htm
2026-02-256-K2026-02-25DIRECTOR/PDMR SHAREHOLDINGa4223u.htm
2026-02-256-K2026-02-25DIRECTOR/PDMR SHAREHOLDINGa4087u.htm
2026-02-256-K2026-02-25GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMAa2524u.htm
2026-02-256-K2026-02-25TRANSACTION IN OWN SHARESa2423u.htm
2026-02-246-K2026-02-24DIRECTOR/PDMR SHAREHOLDINGa2046u.htm
2026-02-246-K2026-02-24TRANSACTION IN OWN SHARESa0740u.htm
2026-02-236-K2026-02-23TRANSACTION IN OWN SHARESa9123t.htm
2026-02-206-K2026-02-20DIRECTOR/PDMR SHAREHOLDINGa8955t.htm
2026-02-206-K2026-02-20TRANSACTION IN OWN SHARESa7374t.htm
2026-02-196-K2026-02-19DIRECTOR/PDMR SHAREHOLDINGa7201t.htm
2026-02-196-K2026-02-19TRANSACTION IN OWN SHARESa5678t.htm
2026-02-186-K2026-02-18TRANSACTION IN OWN SHARESa3988t.htm
2026-02-176-K2026-02-17DIRECTOR/PDMR SHAREHOLDINGa3813t.htm
2026-02-176-K2026-02-17DIRECTOR/PDMR SHAREHOLDINGa3812t.htm
2026-02-176-K2026-02-17GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMMEa2424t.htm
2026-02-176-K2026-02-17EXDENSUR APPROVED BY THE EUROPEAN COMMISSIONa2272t.htm
2026-02-176-K2026-02-17DIRECTOR/PDMR SHAREHOLDINGa2134t.htm
2026-02-176-K2026-02-17DIRECTOR/PDMR SHAREHOLDINGa2133t.htm
2026-02-176-K2026-02-17DIRECTOR/PDMR SHAREHOLDINGa2131t.htm
2026-02-116-K2026-02-11DIRECTOR/PDMR SHAREHOLDINGa6485s.htm
2026-02-116-K2026-02-11DIRECTOR/PDMR SHAREHOLDINGa6433s.htm
2026-02-116-K2026-02-11DIRECTOR/PDMR SHAREHOLDINGa6517s.htm
2026-02-116-K2026-02-11DIRECTOR/PDMR SHAREHOLDINGa6434s.htm
2026-02-106-K2026-02-10CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATIONa3269s.htm
2026-02-096-K2026-02-09DIRECTOR/PDMR SHAREHOLDINGa2925s.htm
2026-02-066-K2026-02-06DIRECTOR/PDMR SHAREHOLDINGa0754s.htm
2026-02-066-K2026-02-06NUCALA COPD APPROVED BY THE EUROPEAN COMMISSIONa9749r.htm
2026-02-056-K2026-02-05DIRECTOR/PDMR SHAREHOLDINGa9347r.htm
2026-02-046-K2026-02-04FINAL RESULTSa5979rv2.htm
2026-02-026-K2026-02-02TOTAL VOTING RIGHTSa3536r.htm
2026-01-266-K2026-01-26EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+a3210q.htm
2026-01-206-K2026-01-20GSK TO ACQUIRE RAPT THERAPEUTICSa5855p.htm
2026-01-206-K2026-01-20AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDINGa5133p.htm
2026-01-166-K2026-01-16DIRECTOR/PDMR SHAREHOLDINGa2968p.htm
2026-01-156-K2026-01-15DIRECTOR/PDMR SHAREHOLDINGa1040p.htm
2026-01-136-K2026-01-13DIRECTOR/PDMR SHAREHOLDINGa7452o.htm
2026-01-076-K2026-01-07EC APPROVAL OF SHINGRIX PFSa8985n.htm
2026-01-076-K2026-01-07POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSENa8987n.htm
2026-01-066-K2026-01-06EXDENSUR APPROVED IN JAPANa7173ngsk.htm
2026-01-056-K2026-01-05DIRECTOR/PDMR SHAREHOLDINGa6964n.htm
2026-01-056-K2026-01-05TOTAL VOTING RIGHTSa6835n.htm
2026-01-056-K2026-01-05NUCALA FOR ADULTS WITH COPD APPROVED IN CHINAa6236ngsk.htm
Advertisement